Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)

27. August 2026 aktualisiert von: Wan-Chuan Tsai, Far Eastern Memorial Hospital

Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients

Patients with end-stage kidney disease (ESKD) rely on maintenance hemodialysis. While high-flux hemodialysis improves small solute clearance, its removal of middle-molecule uremic toxins (e.g., α1-microglobulin [α1-MG]) remains insufficient, contributing to symptoms such as restless legs syndrome (RLS), pruritus, and poor sleep quality, which are also linked to increased cardiovascular risk. In this study, the investigators evaluate whether using a "Super High-Flux" dialyzer (a Type V high-performance dialyzer) during hemodialysis can safely improve the removal of middle-molecule uremic toxins-specifically α1-microglobulin (α1-MG)-and relieve RLS symptoms in maintenance hemodialysis patients.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.

In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.

It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.

This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Wan-Chuan Tsai, M.D., Ph.D.
  • Telefonnummer: 1780 886-289667000
  • E-Mail: mkks618@gmail.com

Studienorte

    • Banciao Dist.
      • New Taipei City, Banciao Dist., Taiwan, 220
        • Far Eastern Memorial Hospital
        • Kontakt:
          • Wan-Chuan Tsai, M.D., Ph.D.
          • Telefonnummer: 1780 886-277281780
          • E-Mail: mkks618@gmail.com

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Diagnosis of Restless Legs Syndrome according to standard criteria.
  2. Age ≥ 20 years.
  3. Maintenance high-flux hemodialysis for ≥ 3 months.
  4. Stable vascular access (AV fistula or AV graft).
  5. Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
  6. Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
  7. Clinically stable condition for the past 4 weeks.
  8. Able and willing to comply with study protocol

Exclusion Criteria:

  1. Low-flux HD or temporary catheter use
  2. Serum albumin < 2.5 g/dL
  3. Recent hospitalization (within 4 weeks)
  4. Scheduled kidney transplantation
  5. Active malignancy or infection
  6. Pregnancy
  7. Any condition impairing protocol adherence

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
Kein Eingriff: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit. The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline in International Restless Legs Scale (IRLS) Score
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity). Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum Albumin Level
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses sleep quality. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in 5-D Itch Scale Score
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses pruritus severity. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses quality of life. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Kappa Free Light Chains Reduction ratio
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Lambda Free Light Chains Reduction ratio
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Zeitfenster: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

30. September 2029

Studienanmeldedaten

Zuerst eingereicht

27. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. August 2026

Zuerst gepostet (Tatsächlich)

31. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

31. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • FEMH-IRB-TSAI2025
  • FEMH-IIT-2026-01 (Andere Zuschuss-/Finanzierungsnummer: Far Eastern Memorial Hospital)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Individual-level deidentified participant data will be made available by the corresponding author of the paper upon request by email. The data will be available for 3 years after formal publication.

IPD-Sharing-Zeitrahmen

The data will become available after completing the study for 1 year and for 3 years after formal publication.

IPD-Sharing-Zugriffskriterien

Data will be made available by the corresponding author of the paper upon request by email.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .